Publications by authors named "J Gregorova"
Article Synopsis
- Researchers synthesized eighteen new compounds called 2-trifluoromethylcinnamanilides and studied their effects against Mycobacterium smegmatis and Plasmodium falciparum, with promising results for certain substituted variants.
- The most effective compounds against M. smegmatis were those with specific trifluoromethyl substitutions, while several anilides also showed strong activity against P. falciparum, with some comparable to chloroquine.
- Initial cytotoxicity tests revealed that some compounds had toxic effects, but others did not, and further studies indicated that two compounds were stable and did not interfere with liver metabolism, enhancing their potential as dual-action antimicrobials.
Article Synopsis
- Multiple myeloma (MM) is a complex blood cancer characterized by the expansion of abnormal plasma cells in the bone marrow, resulting in symptoms like bone damage, low blood cell counts, and kidney issues.
- Despite improved treatments, the disease often relapses, and its development is linked to genomic instability, particularly a phenomenon called chromothripsis, which causes major chromosome shattering and rearrangement.
- This review aims to summarize key chromosomal abnormalities in MM, with an emphasis on how chromothripsis contributes to the disease's complexity and opens up potential avenues for better diagnostics and understanding of its underlying mechanisms.
Multiple myeloma (MM) is the second most prevalent hematological malignancy, characterized by infiltration of the bone marrow by malignant plasma cells. Extramedullary disease (EMD) represents a more aggressive condition involving the migration of a subclone of plasma cells to paraskeletal or extraskeletal sites. Liquid biopsies could improve and speed diagnosis, as they can better capture the disease heterogeneity while lowering patients' discomfort due to minimal invasiveness.
View Article and Find Full Text PDFAim: The aim of this study was to develop a vancomycin population pharmacokinetic model in adult obese patients and propose covariate-based dosing individualization in order to maximize the achievement of the newly recommended PK/PD target, according to a revised consensus guideline from 2020.
Methods: Therapeutic drug monitoring data from initial vancomycin therapy (first 3 days of treatment) in adult obese (BMI ≥ 30 kg/m) patients from 2013 to 2022 were analyzed using a non-linear mixed-effects modeling method, and Monte Carlo simulations were then used to find the optimal dosage maximizing the PK/PD target attainment.
Results: A total of 147 vancomycin serum levels obtained from 138 patients were included in the analysis.
Background: Pazopanib, an anti-angiogenic multitarget tyrosine kinase inhibitor, has been approved for the treatment of metastatic renal cell carcinoma and soft tissue sarcoma. However, its recommended dose does not always produce consistent outcomes, with some patients experiencing adverse effects or toxicity. This variability is due to differences in the systemic exposure to pazopanib.
View Article and Find Full Text PDF